Clinical Trial Search

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Ejection Fraction — 33; 30; 25 % of blood ejected with each beat

Primary: Cohort Retention — 16; 7 participants

Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL

Primary: Hospital Length of Stay — 7; 8 days

Primary: Peak VO2 — 14.5; 12.9 ml/kg/min

Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001

Primary: Number of Subjects With Adverse Drug Reactions (ADRs) — 61 Participants

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90

Primary: All Cause Mortality — 163; 118 participants

Primary: Patient Quality of Life as Measured on the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score — 54.2; 51.1 score on a scale

Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade

Primary: Medication Adherence — 91.2; 85.5 percentage of days covered

Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 386; 502 Participants — p=<0.0001

Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842

Primary: Evaluate the Reduction in Left-ventricular End Systolic Volume Index (LVESVi) After 6 Months of Spinal Cord Stimulation (SCS) Therapy in the Treatment Arm Compared to…

Primary: Re-hospitalization or Death — 48; 48 participants

Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 5; 5; 7 Participants

Primary: Patient Well Being, as Determined by a Visual Analog Scale — 4236; 4372.7; 4170.8; 4429.6 units on a scale

Primary: Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D) — 0; 1; 2; 5 participants

Primary: Treatment Tolerability: Number of Participants Without Discontinuation of Study Intervention (Incl. Max. 1 Day Interruption) and Without Moderate to Severe Symptomatic…

Primary: Number of Participants With Treatment Related AEs and Serious Adverse Events (SAEs) — 0 Participants

Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min

Primary: Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months. — 277 Participants

Primary: Goal Attainment of Preventive Health Behaviors as Measured by the Goal Attainment Scale — 40; 40; 57.5; 52.5 t-score

Primary: Change in Serum Potassium — 0.15; 0.05 mg/dl